Idorsia (OTCMKTS:IDRSF) Shares Down 5.4% – Time to Sell?

Idorsia Ltd (OTCMKTS:IDRSF) traded down 5.4% on Thursday. The company traded as low as $5.30 and last traded at $5.30. Approximately 200 shares were traded during mid-day trading, a decline of 98% from the average session volume of 9,700 shares. The stock had previously closed at $5.60.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on IDRSF. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Idorsia in a research report on Monday, August 3rd. HC Wainwright restated a “buy” rating on shares of Idorsia in a research report on Monday, September 14th. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy”.

Idorsia Stock Performance

The company has a 50 day simple moving average of $6.96 and a 200-day simple moving average of $5.96.

Idorsia Company Profile

Idorsia Ltd. is a biopharmaceutical company headquartered in Allschwil, Switzerland. The company was established in 2017 following the acquisition of Actelion by Johnson & Johnson, with Idorsia retaining Actelion’s research and development operations and a portfolio of pharmaceutical assets.

Idorsia discovers and develops medicines for conditions with significant unmet medical needs, focusing primarily on cardiovascular disease, central nervous system disorders, immunology and rare diseases.